As the administration pushes for a return to US manufacturing, outsourcing agreements with domestic manufacturers are ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

HOLLY SPRINGS, N.C. -- Genentech, a leading biotechnology company based in San Francisco, is set to build a $700 million ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the ...

Genentech, a Roche Group company (OTCQX:RHHBY) (OTCQX:RHHBF), said on Tuesday that a U.S. FDA advisory committee voted ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Genentech plans to invest $700 million in a new facility in Holly Springs, North Carolina, creating 420 jobs and joining the ...

The biotech giant's new facility is part of a larger U.S. investment strategy, though it may roll back its buildout if the ...

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients ...